Start-Up Quarterly Statistics, Q2 2010
This article was originally published in Start Up
Executive Summary
Highlights from the Q2 2010 review of start-up dealmaking: Biopharma, medical device and in vitro diagnostics startups raised a total of $606 million, an 83% hike from the previous quarter but a 30% drop from Q2 2009. Unlike Q1, which saw four spin-offs, Q2 had just one. Three acquisitions closed including J&J's purchase of respiratory-focused RespiVert. During the second quarter of 2010, several companies signed multiple agreements including Clovis Oncology.
You may also be interested in...
TetraPhase's Series C
Anti-infective developer TetraPhase Pharmaceuticals announced June 1 its $45 million Series C financing, with participation from a syndicate of new and existing backers. The financing is one of the richest of the year, just below the April $56 million Series C pulled in by Achaogen, which is also developing antibiotics for drug resistant diseases. And it far exceeds the average Series C financing of $19.77 million raised between January and May of this year.
St. Jude Joins with iRhythm in Wireless Cardiac Monitoring
iRhythm Technologies, which has been quietly working on a new platform in arrhythmia monitoring since 2006, came forward with much éclat at the 2010 Heart Rhythm Society Meeting in May. There the company made a two-part announcement: the signing of a co-marketing agreement with St. Jude Medical Inc. and a $10 million Series B round led by St. Jude, with the participation of existing investors Mohr Davidow Ventures, Synergy Life Science Partners, and two additional undisclosed investors. The co-marketing agreement provides validation for the young company operating in a new field, and for its established big partner, a way to use a new diagnostic technology to assure more efficient use of its therapeutic equipment by the health care system.
Use Of Protein Biomarkers Punctuates Clovis' Fast-Paced Clinical Trials Strategy
A year ago, Clovis Oncology secured $145 million in start-up financing, the largest A round ever for a biotech. Now, the firm has mapped out a potential clinical trials and approval track for its first therapeutics program. And under a deal announced in April, development of that first drug, a lipid-conjugated formulation of the chemotherapy drug gemcitabine, will include a companion diagnostic developed and sold by Ventana Medical Systems.